| In millions, except per share items | Sep-30-22 | Sep-30-21 | Sep-30-20 | Sep-30-19 | Sep-30-18 | Sep-30-17 | Sep-30-16 | Sep-30-15 |
| | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| MDx Testing Services | 16.2 | 6.7 | | | | | | |
| Therapeutic DNA Production | 0.4 | 0.6 | | | | | | |
| Europe | 0.4 | 0.4 | | | | | | |
| DNA Tagging and Security Products | 1.6 | 1.7 | | | | | | |
| Total revenues [+] | 18.2 | 9.0 | 1.9 | 5.4 | 3.9 | 4.8 | 4.2 | 9.0 |
| Products | | | | | | | 2.5 | 5.4 |
| Services | | | | | | | 1.6 | 3.6 |
| Revenue growth [+] | 101.3% | 367.4% | -64.2% | 38.1% | -17.8% | 13.5% | -53.5% | 231.0% |
| MDx Testing Services | 139.8% | | | | | | | |
| Therapeutic DNA Production | -21.4% | | | | | | | |
| Europe | 24.9% | | | | | | | |
| DNA Tagging and Security Products | -9.0% | | | | | | | |
| Cost of goods sold | 13.1 | 4.5 | 0.8 | 0.9 | 1.2 | 1.1 | 1.2 | 0.4 |
| Gross profit | 5.1 | 4.5 | 1.1 | 4.5 | 2.7 | 3.7 | 3.0 | 8.6 |
| Gross margin | 27.8% | 49.7% | 57.1% | 83.7% | 69.1% | 77.3% | 72.0% | 95.7% |
| Selling, general and administrative | 15.1 | 12.8 | 10.0 | 10.3 | 11.0 | 13.3 | 10.8 | 13.4 |
| Research and development | 3.9 | 4.2 | 3.3 | 3.0 | 2.8 | 2.3 | 3.7 | 2.6 |
| EBITDA [+] | -12.7 | -11.7 | -12.2 | -8.7 | -11.1 | -12.2 | -11.5 | -7.4 |
| EBITDA growth | 8.5% | -4.6% | 40.3% | -21.3% | -8.9% | 6.0% | 56.1% | -37.8% |
| EBITDA margin | -69.8% | -129.4% | -634.2% | -162.1% | -284.3% | -256.5% | -274.5% | -81.7% |
| Depreciation | 1.3 | 0.8 | 0.2 | 0.3 | 0.4 | 0.1 | 0.5 | 0.4 |
| EBITA | -14.0 | -12.5 | -12.4 | -9.0 | -11.5 | -12.3 | -11.9 | -7.8 |
| EBITA margin | -76.9% | -138.0% | -642.3% | -166.9% | -293.8% | -259.6% | -285.3% | -86.1% |
| Amortization of intangibles | | 0.1 | 0.1 | 0.1 | 0.2 | 0.5 | 0.3 | 0.1 |
| EBIT [+] | -14.0 | -12.5 | -12.5 | -9.1 | -11.6 | -12.8 | -12.2 | -7.9 |
| EBIT growth | 11.5% | -0.1% | 37.4% | -21.7% | -9.2% | 5.1% | 55.3% | -36.0% |
| EBIT margin | -76.9% | -138.8% | -649.0% | -169.3% | -298.4% | -269.8% | -291.4% | -87.2% |
| Non-recurring items [+] | | 0.8 | | | | | | |
| Asset impairment | | 0.8 | | | | | | |
| Interest expense, net [+] | 0.0 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest expense | | | 0.1 | 0.2 | 0.0 | | | 0.0 |
| Interest income | 0.0 | 0.0 | | | | 0.0 | 0.0 | |
| Other income (expense), net [+] | 5.7 | -0.9 | -0.4 | 0.7 | 0.0 | 0.0 | 0.0 | -4.0 |
| Gain (loss) on debt retirement | | -1.8 | | -1.3 | | | | |
| Change in fair value of warrants | 18.0 | | | | | | | |
| Other | 0.0 | 0.0 | -0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax income | -8.3 | -14.3 | -13.0 | -8.6 | -11.7 | -12.9 | -12.2 | -11.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | | 0.0% | 0.0% | 0.0% | 0.0% |
| Minority interest | 0.0 | 0.0 | 0.0 | 0.0 | | | | |
| Net income | -8.4 | -14.3 | -13.0 | -8.9 | -11.7 | -12.9 | -12.2 | -11.9 |
| Net margin | -46.1% | -158.3% | -674.6% | -165.8% | -299.6% | -270.6% | -290.8% | -131.9% |
| |
| Basic EPS [+] | ($0.93) | ($2.07) | ($3.32) | ($9.69) | ($15.86) | ($0.49) | ($0.51) | ($0.63) |
| Growth | -54.8% | -37.9% | -65.7% | -38.9% | 3153.5% | -5.2% | -18.1% | -35.1% |
| Diluted EPS [+] | ($0.93) | ($2.07) | ($3.32) | ($9.69) | ($15.86) | ($0.49) | ($0.51) | ($0.63) |
| Growth | -54.8% | -37.9% | -65.7% | -38.9% | 3153.5% | -5.2% | -18.1% | -35.1% |
| |
| Shares outstanding (basic) [+] | 9.0 | 6.9 | 3.9 | 0.9 | 0.7 | 26.4 | 23.7 | 18.9 |
| Growth | 29.6% | 76.5% | 325.2% | 25.0% | -97.2% | 11.3% | 25.1% | 40.1% |
| Shares outstanding (diluted) [+] | 9.0 | 6.9 | 3.9 | 0.9 | 0.7 | 26.4 | 23.7 | 18.9 |
| Growth | 29.6% | 76.5% | 325.2% | 25.0% | -97.2% | 11.3% | 25.1% | 40.1% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |